市場調查報告書
商品編碼
1370623
近距離放射治療設備市場 - 按產品類型、技術、按應用、最終用途 - 全球預測,2023-2032 年Brachytherapy Devices Market - By Product Type, By Technique, By Application, By End-use - Global Forecast, 2023-2032 |
2023 年至2032 年,全球近距離放射治療設備市場規模將以6.2% 的年複合成長率成長。全球癌症(尤其是前列腺癌和子宮頸癌)發病率的不斷上升,正在推動對近距離放射治療手術的需求,推動產業成長。
此外,技術的進步帶來了更精確、更有效率的近距離放射治療設備,減少了副作用並縮短了治療持續時間。總部位於瑞典斯德哥爾摩的 Elekta AB 在 2021 年阿拉伯健康大會上推出了其創新的介入放射治療解決方案。這些解決方案針對癌症護理和腦部疾病進行個性化設計,主要針對腫瘤,同時確保患者安全。
人們越來越認知到微創癌症治療方案的好處,這將進一步推動業務成長。有利的報銷政策和人口老化也將推動市場擴張。
近距離治療設備市場根據產品類型、技術、應用、最終用途和地區進行分類。
電子近距離放射治療產品領域 2023 年至 2032 年的年複合成長率將達到 6.5%。電子近距離放射治療的非侵入性、減少健康組織的輻射暴露以及更短的治療時間將推動該領域的成長。此外,電子近距離治療設備的技術進步使其越來越受歡迎,成為各種癌症的首選治療選擇。
高劑量率 (HDR) 技術到 2032 年將呈現 5.8% 的年複合成長率,這得益於其精確性、更短的治療持續時間以及減少健康組織的輻射暴露。這些優勢將使 HDR 近距離放射治療成為未來幾年癌症治療越來越受歡迎的選擇。
根據應用情況,受乳癌發病率增加、對微創治療的需求以及近距離放射治療提供有針對性和有效放射的能力等因素的推動,預計乳癌細分市場從2023 年到2032 年的複合年增率將達到6%乳癌患者的治療。
從地區來看,受癌症患病率上升、有利的報銷政策以及該地區先進醫療技術的日益採用等因素的推動,到2032 年,歐洲近距離治療設備行業將以6.3% 的年複合成長率成長。人們日益關注盡量減少放射治療的副作用,這將進一步促進該地區產業的成長。
Global brachytherapy devices market size will grow at a 6.2% CAGR from 2023 to 2032. The increasing incidence of cancer worldwide, especially prostate and cervical cancers, is boosting demand for brachytherapy procedures, driving industry growth.
Additionally, advancements in technology are leading to more precise and efficient brachytherapy devices, reducing side effects and treatment durations. Elekta AB, based in Stockholm, Sweden, unveiled its inventive interventional radiotherapy solutions at Arab Health 2021. These solutions, personalized for cancer care and brain disorders, were designed primarily to target tumors while ensuring patient safety.
The growing awareness about the benefits of minimally invasive cancer treatment options will further drive business growth. Favorable reimbursement policies and a rising aging population will also fuel market expansion.
The brachytherapy devices market is categorized based on product type, technique, application, end-use, and region.
The electronic brachytherapy product segment will reflect a 6.5% CAGR over 2023-2032. The non-invasive nature of electronic brachytherapy, its reduced radiation exposure to healthy tissues, and shorter treatment times will drive growth in the segment. Moreover, technological advancements in electronic brachytherapy devices contribute to its rising popularity as a preferred treatment option for various cancers.
The high dose rate (HDR) technique will exhibit a 5.8% CAGR through 2032, driven by its precision, shorter treatment duration, and reduced radiation exposure to healthy tissues. These advantages will make HDR brachytherapy an increasingly preferred choice for cancer treatment in the coming years.
Based on application, the breast cancer segment is anticipated to depict a 6% CAGR from 2023 to 2032, driven by factors such as the increasing incidence of breast cancer, demand for minimally invasive treatments, and the ability of brachytherapy to provide targeted and effective radiation therapy for breast cancer patients.
Regionally, the Europe brachytherapy devices industry will grow at a 6.3% CAGR through 2032, driven by factors such as the rising prevalence of cancer, favorable reimbursement policies, and increasing adoption of advanced medical technologies in the region. The rising focus on minimizing the side effects of radiation therapy will further augment growth in the regional industry.